Clinical Trial Update: Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring neoadjuvant envafolimab with Abraxane and cisplatin for resectable esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• CISPLATIN (cisplatin)
• Envafolimab (envafolimab)

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: Immunotherapy;Envafolimab; Esophageal Cancer | Phase 2 | Status: UNKNOWN